New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
MANHASSET, N.Y., Sept. 6 /PRNewswire-USNewswire/ -- Scientists at The Feinstein Institute for Medical Research have identified a critical gene that increases a person's risk for rheumatoid arthritis and systemic lupus erythematosus, and may be involved with other autoimmune diseases. The genetic link, described in the September 6th issue of the New England Journal of Medicine, was a collaborative effort led by Peter K. Gregersen, MD, head of The Feinstein Institute's Robert S. Boas Center for Genomics & Human Genetics. A decade ago, Dr. Gregersen helped bring together scientists from a dozen institutes to pool patients and add strength in numbers as they collectively hunt for genes. More recently, the North American Rheumatoid Arthritis Consortium (NARAC) studied a region identified on chromosome 2 in previous linkage studies conducted by the same team. In the latest study, they analyzed DNA from 2,500 patients with rheumatoid arthritis (RA) or lupus. Genetic mapping enabled them to identify STAT4 as a culprit in susceptibility to both diseases. "This work required the collection and genotyping of thousands of RA and lupus patients and volunteers, a task that would have been difficult to accomplish without the strong partnerships we forged," said Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The federal institute has supported NARAC since its inception. "Identifying STAT4 as the relevant gene on chromosome 2 is very exciting," added Elaine Remmers, PhD, a lead author in the NEJM study on STAT4 and a staff scientist in the NIAMS's Genetics and Genomics Branch. "We now are faced with trying to figure out how this variant of STAT4 increases a person's risk." About 22 percent of people in the United States inherit this particular form of STAT4. Having this variant of STAT4 confers a 30 percent increased risk for developing rheumatoid arthritis. People with two copies of STAT4 have a 60 percent increased risk, Dr. Gregersen said. Rheumatoid arthritis is a painful inflammatory condition of the joints. It is an autoimmune disease, which means the body's immune system recognizes a product in the lining of the joint as foreign and wages an attack. Patients with lupus, also an autoimmune disease, have about double the risk compared to people without this variant of STAT4. In a companion study by Dr. Gregersen and his colleagues, STAT4 popped up as an important risk gene in a population of patients in Korea. This paper is published this month in Molecular Medicine. One percent of people will develop rheumatoid arthritis. There are probably dozens of genes, perhaps more, involved in triggering complex diseases like rheumatoid arthritis. "Identifying this risk gene is important because it points us in the right direction," said Dr. Gregersen, who also just completed a whole genome-wide association study of rheumatoid arthritis that will appear later this month in the NEJM. The study is online as of September 6th with an accompanying editorial. In this paper, the scientists identified another risk gene -- TRAF1-C5. "The identification of these two new autoimmunity genes has profound significance for our understanding of these complex diseases and our ability to develop more specific diagnostic tests and therapies," said Lindsey Criswell, MD, PhD, professor of medicine at UCSF and a co-investigator on both studies. A lot is known about the STAT4 gene and the protein it makes. STAT4 is a signaling molecule that mediates the effects of immune system cytokines such as IL12 and some types of interferon. STAT4 controls the differentiation of T- cells into TH1 cells and may contribute to the development of TH17 cells, both of which seem to have a role in maintaining chronic inflammation in the body. Inhibiting STAT4 can prevent or ameliorate arthritis in animal models of rheumatoid arthritis, suggesting that STAT4 could be a target for new therapies. The discovery of STAT4 can ultimately help scientists unravel the triggers for the disease, help in the development of a test to confirm a diagnosis and perhaps even help predict who will respond to treatments. The NARAC and collaborators at Celera Diagnostics previously identified PTPN22 as another risk gene in 2004. PTPN22 influences the "trigger point" for activation of T-cells -- immune cells normally called on to wage battle against infection. In autoimmune diseases like rheumatoid arthritis, PTPN22 appears to put people at higher risk of a wayward T-cell response. Dr. Gregersen said that the two genes -- PTPN22 and STAT4 -- appear to work independently to increase the risk for rheumatoid arthritis. These are the first RA genes to be discovered since the 1980s when scientists reported detailed association with genetic variants in the HLA region known as the "shared epitope," work for which Dr. Gregersen is still widely recognized. The key to the new genetic discoveries, Dr. Gregersen said, is to have "more patients and controls. With higher numbers of volunteers, we will have more power to pull out additional new genes and figure out what they do in triggering these diseases. Continued international collaboration with colleagues at the Karolinska Institute in Stockholm will be critical for these efforts." In addition to Drs. Gregersen, Criswell and Remmers, the NARAC investigators on the STAT4 study include Christopher Amos, PhD, of The University of Texas M.D. Anderson Cancer Center; Daniel Kastner MD, PhD, of NIAMS's Genetics and Genomic Branch; Michael F. Seldin MD, PhD, of the University of California, Davis; and Robert M. Plenge, MD, PhD, of the Brigham and Women's Hospital. Timothy W. Behrens, MD, senior director of immunology, tissue growth & repair at Genentech, Inc. was a key collaborator on the lupus research. The NARAC team is also part of the whole genome association study to be published later this month in the NEJM. Other collaborators on this study include Lars Klareskog of the Karolinska Institute; Mark Seielstad of the Genome Institute of Singapore; and John Carulli, PhD, and Evan Beckman, MD, of Biogen Idec in Cambridge, Ma. Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, leukemia, lymphoma, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient. For more information, please visit http://www.FeinsteinInstitute.org or http://feinsteininstitute.typepad.com/feinsteinweblog/ Contact: Jamie Talan 516-562-1232
SOURCE The Feinstein Institute for Medical Research
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.